Nifty
Sensex
:
:
11915.25
39747.28
71.15 (0.60%)
312.56 (0.79%)

Pharmaceuticals & Drugs

Rating :
55/99  (View)

BSE: 500124 | NSE: DRREDDY

2645.00
-18.90 (-0.71%)
27-May-2019 | 12:59PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  2664.00
  •  2669.00
  •  2632.45
  •  2663.90
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  225005
  •  5951.38
  •  2964.00
  •  1872.95

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 44,243.29
  • 22.69
  • 5
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 49,050.89
  • 0.75%
  • 3.15

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 26.77%
  • 3.45%
  • 7.85%
  • FII
  • DII
  • Others
  • 0.21%
  • 14.03%
  • 47.69%

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 7.54
  • 1.26
  • -2.84

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 6.00
  • -6.27
  • -8.09

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 0.11
  • -14.21
  • -24.35

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 24.24
  • 28.44
  • 33.62

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 4.75
  • 4.31
  • 3.51

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 16.83
  • 17.60
  • 17.28

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Var%
Dec 18
Dec 17
Var%
Sep 18
Sep 17
Var%
Jun 18
Jun 17
Var%
Net Sales
4,029.60
3,553.90
13.39%
3,864.60
3,834.10
0.80%
3,817.50
3,559.80
7.24%
3,736.50
3,333.20
12.10%
Expenses
3,210.70
2,990.30
7.37%
3,060.00
3,041.40
0.61%
3,058.20
2,890.40
5.81%
2,967.70
3,010.00
-1.41%
EBITDA
818.90
563.60
45.30%
804.60
792.70
1.50%
759.30
669.40
13.43%
768.80
323.20
137.87%
EBIDTM
20.32%
15.86%
20.82%
20.68%
19.89%
18.80%
20.58%
9.70%
Other Income
83.30
44.90
85.52%
102.30
43.00
137.91%
128.20
31.60
305.70%
50.40
38.00
32.63%
Interest
24.50
17.80
37.64%
24.10
17.20
40.12%
20.80
22.30
-6.73%
19.50
21.50
-9.30%
Depreciation
287.20
276.30
3.94%
290.30
271.50
6.92%
278.60
270.20
3.11%
278.70
259.20
7.52%
PBT
590.50
314.40
87.82%
592.50
547.00
8.32%
588.10
408.50
43.97%
521.00
80.50
547.20%
Tax
150.80
49.20
206.50%
101.10
252.80
-60.01%
80.70
112.30
-28.14%
53.20
23.70
124.47%
PAT
439.70
265.20
65.80%
491.40
294.20
67.03%
507.40
296.20
71.30%
467.80
56.80
723.59%
PATM
10.91%
7.46%
12.72%
7.67%
13.29%
8.32%
12.52%
1.70%
EPS
27.43
16.39
67.36%
30.14
18.26
65.06%
31.22
18.42
69.49%
28.68
4.02
613.43%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Net Sales
15,448.20
14,281.00
14,196.10
15,568.30
15,023.30
13,415.30
11,895.60
9,814.50
7,496.90
6,988.60
6,900.60
Net Sales Growth
8.17%
0.60%
-8.81%
3.63%
11.99%
12.78%
21.20%
30.91%
7.27%
1.28%
 
Cost Of Goods Sold
4,494.80
4,039.50
3,696.50
3,758.50
3,786.40
3,317.10
3,516.80
2,568.30
2,091.10
2,061.70
1,940.40
Gross Profit
10,953.40
10,241.50
10,499.60
11,809.80
11,236.90
10,098.20
8,378.80
7,246.20
5,405.80
4,926.90
4,960.20
GP Margin
70.90%
71.71%
73.96%
75.86%
74.80%
75.27%
70.44%
73.83%
72.11%
70.50%
71.88%
Total Expenditure
12,296.60
11,929.80
11,723.90
11,983.00
11,529.70
10,164.70
9,176.10
7,374.90
5,936.00
5,563.50
5,587.60
Power & Fuel Cost
-
329.30
330.10
315.20
339.10
319.90
335.40
225.90
183.30
141.50
122.70
% Of Sales
-
2.31%
2.33%
2.02%
2.26%
2.38%
2.82%
2.30%
2.45%
2.02%
1.78%
Employee Cost
-
3,214.90
3,106.80
3,117.40
2,944.60
2,475.40
1,928.70
1,591.20
1,304.80
1,183.20
992.00
% Of Sales
-
22.51%
21.88%
20.02%
19.60%
18.45%
16.21%
16.21%
17.40%
16.93%
14.38%
Manufacturing Exp.
-
1,746.50
1,886.60
1,856.40
1,999.10
1,747.60
1,441.30
1,237.00
985.90
921.80
1,115.30
% Of Sales
-
12.23%
13.29%
11.92%
13.31%
13.03%
12.12%
12.60%
13.15%
13.19%
16.16%
General & Admin Exp.
-
1,198.90
1,339.90
1,271.40
1,037.30
1,004.30
796.30
682.90
479.00
413.50
582.30
% Of Sales
-
8.40%
9.44%
8.17%
6.90%
7.49%
6.69%
6.96%
6.39%
5.92%
8.44%
Selling & Distn. Exp.
-
1,330.20
1,293.40
1,181.10
1,357.50
1,264.80
1,119.10
984.40
744.90
691.00
651.30
% Of Sales
-
9.31%
9.11%
7.59%
9.04%
9.43%
9.41%
10.03%
9.94%
9.89%
9.44%
Miscellaneous Exp.
-
70.50
70.60
483.00
65.70
35.60
38.50
85.20
147.00
150.80
651.30
% Of Sales
-
0.49%
0.50%
3.10%
0.44%
0.27%
0.32%
0.87%
1.96%
2.16%
2.66%
EBITDA
3,151.60
2,351.20
2,472.20
3,585.30
3,493.60
3,250.60
2,719.50
2,439.60
1,560.90
1,425.10
1,313.00
EBITDA Margin
20.40%
16.46%
17.41%
23.03%
23.25%
24.23%
22.86%
24.86%
20.82%
20.39%
19.03%
Other Income
364.20
155.20
171.50
295.00
274.10
169.90
149.90
132.30
52.30
103.10
99.40
Interest
88.90
78.80
63.40
82.60
108.20
126.70
100.30
114.10
32.30
38.50
108.20
Depreciation
1,134.80
1,077.20
1,026.60
938.90
759.90
647.50
550.20
518.10
398.10
413.10
497.70
PBT
2,292.10
1,350.40
1,553.70
2,858.80
2,899.60
2,646.30
2,218.90
1,939.70
1,182.80
1,076.60
806.50
Tax
385.80
438.00
296.50
751.10
563.20
683.10
637.90
503.50
183.90
266.80
260.80
Tax Rate
16.83%
32.43%
19.08%
26.27%
19.42%
25.81%
29.47%
27.90%
15.55%
43.15%
-39.74%
PAT
1,906.30
912.40
1,257.20
2,107.70
2,336.40
1,963.20
1,526.80
1,300.90
998.90
351.50
-917.10
PAT before Minority Interest
1,906.30
912.40
1,257.20
2,107.70
2,336.40
1,963.20
1,526.80
1,300.90
998.90
351.50
-917.10
Minority Interest
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
PAT Margin
12.34%
6.39%
8.86%
13.54%
15.55%
14.63%
12.83%
13.25%
13.32%
5.03%
-13.29%
PAT Growth
108.93%
-27.43%
-40.35%
-9.79%
19.01%
28.58%
17.36%
30.23%
184.18%
138.33%
 
Unadjusted EPS
117.47
57.08
77.53
124.93
137.18
115.45
89.93
76.76
59.06
20.83
-54.48

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Shareholder's Funds
12,571.60
12,262.10
12,569.80
9,853.10
7,865.20
6,369.10
4,989.00
4,031.90
3,776.80
3,526.10
Share Capital
83.00
82.90
85.30
85.20
85.10
84.90
84.80
84.60
84.40
84.20
Total Reserves
12,406.00
12,098.80
12,393.90
9,677.40
7,698.60
6,215.30
4,849.10
3,906.80
3,657.40
3,403.00
Non-Current Liabilities
2,538.40
456.10
876.70
1,678.40
2,182.30
1,285.10
1,609.80
600.30
1,491.00
2,051.40
Secured Loans
63.00
59.70
74.70
77.50
94.70
80.20
26.10
24.40
26.90
38.60
Unsecured Loans
2,445.90
485.20
993.80
1,354.00
1,980.80
1,185.70
1,615.80
512.80
1,457.10
1,959.00
Long Term Provisions
81.70
84.20
95.20
77.90
56.30
51.40
33.30
28.80
0.00
0.00
Current Liabilities
6,893.80
8,419.90
6,347.10
6,821.30
5,790.40
5,658.80
4,591.40
4,208.50
2,024.80
1,711.20
Trade Payables
1,334.50
1,056.90
906.80
867.30
893.20
965.70
756.60
634.50
1,667.90
1,505.60
Other Current Liabilities
2,411.40
2,339.70
2,409.10
2,624.40
2,020.80
2,120.40
1,749.20
1,328.90
6.70
6.20
Short Term Borrowings
2,556.20
4,362.60
2,271.80
2,185.70
2,060.70
1,898.60
1,588.80
1,831.90
0.00
0.00
Short Term Provisions
591.70
660.70
759.40
1,143.90
815.70
674.10
496.80
413.20
350.20
199.40
Total Liabilities
22,003.80
21,138.10
19,793.60
18,352.80
15,837.90
13,313.00
11,190.20
8,840.70
7,292.60
7,288.70
Net Block
6,968.00
6,930.70
6,563.00
5,377.00
4,640.80
4,050.60
3,411.70
3,385.50
2,352.20
2,927.00
Gross Block
17,436.30
15,932.40
15,019.70
12,573.60
11,917.60
10,089.40
8,842.30
7,975.10
6,446.80
6,502.70
Accumulated Depreciation
10,463.00
9,001.70
8,456.70
7,169.90
7,276.80
5,984.60
5,295.30
4,589.60
4,094.60
2,112.90
Non Current Assets
11,505.40
11,454.40
7,999.60
6,476.10
5,512.20
4,786.30
4,191.20
4,025.70
3,115.00
3,357.20
Capital Work in Progress
3,470.50
3,324.50
772.20
529.00
638.80
565.30
708.50
575.20
762.20
429.60
Non Current Investment
465.30
682.60
329.70
145.60
0.40
0.40
0.90
0.90
0.60
0.60
Long Term Loans & Adv.
564.80
482.10
290.40
418.10
232.20
149.10
70.10
64.10
0.00
0.00
Other Non Current Assets
36.80
34.50
44.30
6.40
0.00
20.90
0.00
0.00
0.00
0.00
Current Assets
10,498.40
9,683.70
11,794.00
11,876.70
10,325.70
8,526.70
6,999.00
4,815.00
4,177.60
3,931.50
Current Investments
1,833.00
1,427.10
3,503.40
2,102.20
1,066.40
196.60
207.00
0.00
357.40
51.70
Inventories
2,908.90
2,852.80
2,557.90
2,569.90
2,418.80
2,170.70
1,943.30
1,599.20
1,339.40
1,325.00
Sundry Debtors
4,052.70
3,798.60
4,125.00
4,101.20
3,325.30
3,180.40
2,536.80
1,761.10
1,159.90
1,440.60
Cash & Bank
263.80
386.50
492.10
1,872.40
2,300.60
2,017.10
1,606.10
575.10
660.00
562.30
Other Current Assets
1,440.00
451.50
393.10
226.20
1,214.60
961.90
705.80
879.60
660.90
551.90
Short Term Loans & Adv.
958.30
767.20
722.50
1,004.80
1,044.20
796.90
611.60
763.20
658.70
551.20
Net Current Assets
3,604.60
1,263.80
5,446.90
5,055.40
4,535.30
2,867.90
2,407.60
606.50
2,152.80
2,220.30
Total Assets
22,003.80
21,138.10
19,793.60
18,352.80
15,837.90
13,313.00
11,190.20
8,840.70
7,292.60
7,288.70

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Cash From Operating Activity
1,803.00
2,144.40
3,262.60
2,523.50
1,969.70
1,377.90
1,612.60
755.40
1,315.00
599.10
PBT
1,350.40
1,553.70
2,858.80
2,899.60
2,646.30
2,164.70
1,804.40
1,182.80
618.30
-656.30
Adjustment
1,625.30
1,687.30
1,107.70
1,654.00
1,042.70
1,062.80
1,157.40
530.10
1,117.30
2,080.10
Changes in Working Capital
-896.60
-519.60
-2.50
-1,483.70
-1,005.00
-1,294.40
-893.80
-658.70
-137.50
-545.60
Cash after chg. in Working capital
2,079.10
2,721.40
3,964.00
3,069.90
2,684.00
1,933.10
2,068.00
1,054.20
1,598.10
878.20
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-276.10
-577.00
-701.40
-546.40
-714.30
-555.20
-455.40
-298.80
-283.10
-279.10
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-1,488.30
-1,840.40
-2,039.40
-2,264.70
-1,694.10
-1,446.30
-1,888.40
-898.80
-710.20
-505.00
Net Fixed Assets
-683.20
-1,019.30
-1,892.20
-828.10
-819.60
-530.80
-554.40
-399.90
-602.60
-571.80
Net Investments
-534.60
1,974.20
-1,213.80
-1,055.80
-427.30
98.50
-15.70
93.10
-851.30
226.80
Others
-270.50
-2,795.30
1,066.60
-380.80
-447.20
-1,014.00
-1,318.30
-592.00
743.70
-160.00
Cash from Financing Activity
-444.00
-369.20
-1,700.10
-433.20
-24.20
-156.80
389.10
44.50
-531.70
-265.10
Net Cash Inflow / Outflow
-129.30
-65.20
-476.90
-174.40
251.40
-225.20
113.30
-98.90
73.10
-171.00
Opening Cash & Equivalents
377.80
492.10
539.50
862.40
520.40
736.20
573.00
660.00
562.30
744.70
Closing Cash & Equivalent
254.20
377.80
492.10
582.90
862.40
520.40
736.20
575.10
660.00
562.30

Financial Ratios

Consolidated /

Standalone
Description
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Book Value (Rs.)
752.35
734.72
731.49
572.92
457.33
371.04
290.91
235.90
221.67
207.08
ROA
4.23%
6.14%
11.05%
13.67%
13.47%
12.46%
12.99%
12.38%
4.82%
-12.24%
ROE
7.40%
10.20%
18.95%
26.63%
27.88%
27.18%
29.15%
25.83%
9.72%
-23.07%
ROCE
8.21%
9.77%
19.55%
22.69%
24.77%
24.79%
26.24%
20.84%
12.18%
-9.14%
Fixed Asset Turnover
0.86
0.92
1.13
1.23
1.23
1.26
1.17
1.04
1.09
1.16
Receivable days
100.33
101.86
96.43
89.72
87.97
87.19
79.59
70.77
67.20
55.01
Inventory Days
73.63
69.56
60.11
60.27
62.06
62.74
65.60
71.20
68.85
63.79
Payable days
37.10
31.00
28.67
28.48
33.96
34.99
35.37
72.19
108.29
85.61
Cash Conversion Cycle
136.86
140.42
127.87
121.51
116.06
114.93
109.82
69.78
27.76
33.19
Total Debt/Equity
0.41
0.40
0.27
0.44
0.58
0.58
0.66
0.59
0.40
0.57
Interest Cover
18.14
25.51
35.61
27.80
21.89
22.58
16.81
37.62
17.06
-5.07

News Update


  • Dr Reddy’s Lab to spend upto $300 million on R&D in FY20
    20th May 2019, 16:32 PM

    The R&D spends for the January-March quarter of FY19 is $53 million

    Read More
  • Dr. Reddy's laboratories reports 66% rise in Q4 consolidated net profit
    17th May 2019, 16:45 PM

    Total consolidated income of the company rose 14.29% at Rs 4,112.90 crore for quarter ended March 31, 2019

    Read More
  • Dr. Reddys Lab - Quarterly Results
    17th May 2019, 15:00 PM

    Read More
  • Dr. Reddy's Lab launches Daptomycin for Injection
    15th May 2019, 10:40 AM

    The Injection is available in single-dose 15 ml vials containing 500 mg of daptomycin

    Read More
  • Dr. Reddy's Lab launches Testosterone Gel
    6th May 2019, 10:31 AM

    Dr. Raddy's Testosterone Gel 1.62% (20.25 mg/1.25 g pump actuation) is available in a net quantity of 88 g pump which dispenses 20.25 mg of testosterone per actuation

    Read More
  • Dr Reddy's starts recall of anti-seizure drug in US market: Report
    26th Apr 2019, 15:16 PM

    The company has started recalling of Divalproex 100-count and 500-count bottles, totaling 33,958 bottles on April 11, 2019

    Read More
  • Dr Reddy's gets nod for anti-platelet drug in China
    26th Apr 2019, 10:34 AM

    The company believes that the sales from this product will not be material in FY20

    Read More
  • Dr. Reddys Lab receives EIR from USFDA for Formulations Plant 3 in Hyderabad
    16th Apr 2019, 08:57 AM

    This site had undergone an audit by the USFDA, wherein the company were issued a Form 483

    Read More
  • Dr. Reddy's Lab to acquire portfolio of 42 ANDAs in US
    15th Apr 2019, 09:54 AM

    The portfolio includes more than 30 generic injectable products

    Read More
  • Dr. Reddy’s Laboratories enters into confidential settlement agreement with Celgene
    2nd Apr 2019, 10:21 AM

    The parties agreed to discontinue all legal proceedings involving certain of Celgene’s Canadian patents related to Lenalidomide

    Read More
  • Dr. Reddy’s Laboratories’ arm declares sale, assignment of US rights to Encore Dermatology
    2nd Apr 2019, 09:23 AM

    Promius Pharma is eligible to receive an upfront payment and future milestone payments contingent upon achievement of certain commercial objectives

    Read More
  • Dr. Reddy's Laboratories launches Tadalafil Tablets in US Market
    27th Mar 2019, 11:45 AM

    The company’s Tadalafil Tablets are available in four strengths including 2.5 mg, 5 mg, 10 mg, and 20 mg, each in 30-count bottle size

    Read More
  • USFDA completes audit at Dr. Reddy's subsidiary in Hyderabad
    23rd Mar 2019, 09:34 AM

    No FDA 483 was issued at the end of inspection

    Read More
  • Dr. Reddy's Laboratories launches B2B customer service portal ‘XCEED’
    19th Mar 2019, 09:55 AM

    The portal is focused on meeting the growing demand for the company’s portfolio of generic APIs

    Read More
  • USFDA completes audit at Dr. Reddy's Louisiana Plant
    22nd Feb 2019, 12:37 PM

    The USFDA has completed audit with one observation

    Read More
  • Dr Reddy's Laboratories recalls 2,770 bags of epilepsy injection in US
    22nd Feb 2019, 09:25 AM

    The reason for recall is the pre-printed text on the primary infusion bag and NDC incorrectly identifies the product as Levetiracetam in 0.75 percent Sodium Chloride

    Read More
  • Dr. Reddy's Lab re-launches Buprenorphine and Naloxone Sublingual Film
    21st Feb 2019, 09:02 AM

    The re-launch comes on the heels of a favorable decision issued by the United States Court of Appeals for the Federal Circuit

    Read More
  • Dr. Reddy's Lab gets EIR for formulations facility in Visakhapatnam
    18th Feb 2019, 09:38 AM

    The company has received EIR from USFDA for FTO VII

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.